Finding – Page 18

Lilly’s Zepbound Outshines Novo’s Wegovy in First Head-to-Head Weight Loss Study

11 months ago talkbio0Tagged Eli, Eli Lilly, Nordisk, Obesity, SURMOUNT-5, Wegovy, Weight Loss, Zepbound

Eli Lilly, Novo Nordisk, Zepbound, Wegovy, Weight Loss, Obesity Treatment, Head-to-Head Study, SURMOUNT-5

UnitedHealthcare CEO Brian Thompson Fatally Shot in Targeted Attack Outside New York City Hotel

11 months ago talkbio0Tagged Brian Thompson, cellular targeting, CEO, Hotel, investor, Killing, New York City, Shooting sensation quality, UnitedHealthcare

UnitedHealthcare, CEO Brian Thompson, targeted killing, New York City, hotel shooting, investor meeting

Acadia Pharmaceuticals Secures Exclusive License for SAN711, a Novel Essential Tremor Treatment

11 months ago talkbio0Tagged Acadia, Allosteric Modulator, Essential Tremor, Positive, SAN711, Saniona

Acadia Pharmaceuticals, SAN711, Essential Tremor, Licensing Agreement, Saniona, GABAA-α3 Positive Allosteric Modulator

Merck Advances with Winrevair: Positive Phase III Results in Severe Pulmonary Arterial Hypertension (PAH) Study

11 months ago talkbio0Tagged Cardiovascular system, Merck, Morbidity - disease rate, Mortality Vital Statistics, PAH, Phase III, Pulmonary arterial hypertension, Winrevair, ZENITH study

Merck, Winrevair, PAH, Phase III, ZENITH study, pulmonary arterial hypertension, cardiovascular drug, morbidity, mortality

AstraZeneca Halts Development of Opioid Use Disorder Drug Due to Antifungal Interaction

11 months ago talkbio0Tagged Antifungal Agents, AstraZeneca, Clinical Trials, Drug Development, Opioid Use Disorder, Social Interaction

AstraZeneca, Opioid Use Disorder, Drug Development, Antifungal Interaction, Clinical Trials

Versant Ventures Launches Pep2Tango Therapeutics with Revolutionary Tetra-Receptor Agonist Approach for Obesity Treatment

11 months ago talkbio0Tagged Amylin, Calcitonin Receptor, GIP/, GLP-1, muscle mass, Next, Next-generation weight loss therapies, Obesity, Pep2Tango, Peptides, Tetra-receptor, Ventures, Versant

Obesity treatment, Tetra-receptor agonist peptides, GLP-1/ GIP/ amylin/ and calcitonin receptors, Muscle mass preservation, Next-generation weight loss therapies, Versant Ventures, Pep2Tango Therapeutics Inc.

Unlocking Health Equity: Leveraging Comprehensive SDOH Market Insights for Enhanced Treatment, Access, and Adherence

11 months ago talkbio0Tagged Adherence, Adherence (attribute), Data Analytics, Health care facility, Health Equity, Market, outcomes, public health medicine (field), Social Determinants of Health

Social Determinants of Health (SDOH), Health Equity, Market Insights, Treatment Access, Adherence, Healthcare Outcomes, Data Analytics, Public Health

GUBamy, a Weekly Amylin Agonist, Shows Promising Weight Loss and Tolerability in Phase 1 Trial

12 months ago talkbio0Tagged Agonist, Amylin, GUBamy, long-acting, Obesity, phase 1 trial, Weight Loss

Amylin agonist, Obesity treatment, Weight loss, Phase 1 trial, GUBamy, Long-acting amylin agonist

UK Health Secretary Warns Against Misuse of GLP-1 Weight Loss Drugs for Aesthetic Purposes

12 months ago talkbio0Tagged agonists, Cautionary Warning, Esthetics (discipline), Glucagon-Like Peptide 1, health secretary, MHRA, MISUSE, UK, Weight Loss, Weight-Loss Agents

GLP-1 agonists, weight loss drugs, misuse, aesthetic weight loss, UK health secretary, MHRA warnings

Rapport Therapeutics Faces Regulatory Hurdles in Pain Treatment Trials

12 months ago talkbio0Tagged Clinical Development, RAP-219, Rapport Therapeutics, regulatory, treatment pain

Rapport Therapeutics, pain treatment trials, regulatory challenges, RAP-219, clinical development